Eli Lilly and Company (NYSE:LLY) Shares Sold by Draper Asset Management LLC

Draper Asset Management LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 14.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,052 shares of the company's stock after selling 677 shares during the period. Eli Lilly and Company comprises approximately 2.6% of Draper Asset Management LLC's holdings, making the stock its 8th largest holding. Draper Asset Management LLC's holdings in Eli Lilly and Company were worth $3,347,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. WestEnd Advisors LLC grew its stake in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the last quarter. Citizens National Bank Trust Department lifted its holdings in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company in the first quarter valued at approximately $40,000. Mascagni Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $43,000. Finally, Prudent Man Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $48,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.3%

LLY stock traded up $2.69 during mid-day trading on Friday, reaching $793.34. The company had a trading volume of 2,851,585 shares, compared to its average volume of 3,670,273. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The company has a market capitalization of $751.88 billion, a price-to-earnings ratio of 64.55, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40. The firm has a fifty day simple moving average of $767.03 and a 200 day simple moving average of $800.01.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. Eli Lilly and Company's revenue was up 45.2% on a year-over-year basis. During the same period last year, the business posted $2.58 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.76%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Analysts Set New Price Targets

Several analysts recently commented on LLY shares. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Morgan Stanley reiterated an "overweight" rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday. UBS Group dropped their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Guggenheim boosted their price target on Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a research report on Friday. Finally, Cantor Fitzgerald began coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average target price of $1,012.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.